Aardvark Therapeutics, Inc. Common Stock (AARD) Earnings Analysis

Aardvark Therapeutics, Inc. Common Stock (AARD) next reports earnings on 2026-08-12, consensus EPS -0.87 USD. Last quarter (2026-05-07) it missed with EPS -0.99 USD vs -0.87652 USD est (-12.9%). It has beaten estimates in 2/5 recent quarters (40%). Trailing P/E -2.02.

Last updated 2026-07-23 · Source: FMP fundamentals + earnings calendar (company filings); consensus from sell-side analyst grades

When does AARD next report earnings?

Next earnings date2026-08-12
Consensus EPS estimate-0.87 USD
Revenue estimaten/a

AARD earnings history — beats and misses

Quarter (report date)EPS actualEPS est.SurpriseResult
2026-05-07-0.99 USD-0.87652 USD-12.9%Miss
2026-03-23-0.81 USD-0.82727 USD+2.1%Beat
2025-11-13-0.75 USD-0.79857 USD+6.1%Beat
2025-08-13-0.66 USD-0.6 USD-10%Miss
2025-02-26-0.68005 USD-0.41 USD-65.9%Miss
2024-09-30-0.32395 USDn/an/an/a

Beat rate: 2/5 (40%) over reported quarters with consensus data.

AARD valuation and analyst view

Trailing P/E-2.02
Trailing EPS-3.20265 USD
Price / book1.63
Dividend yield0.00%
Market cap0.13B
Analyst consensusBuy (4 buy / 4 hold / 1 sell)
Avg price target3 USD

Related research pages

Frequently asked questions

When is Aardvark Therapeutics, Inc. Common Stock (AARD)'s next earnings date?

Aardvark Therapeutics, Inc. Common Stock is next scheduled to report on 2026-08-12, with a consensus EPS estimate of -0.87 USD.

Did AARD beat earnings last quarter?

In its 2026-05-07 report, AARD posted EPS of -0.99 USD versus a -0.87652 USD estimate — a miss of 12.9%.

What is AARD's earnings track record?

Over the last 5 reported quarters with consensus data, AARD beat estimates 2 times (40%).

What is AARD's current P/E ratio and EPS?

AARD trades at a trailing P/E of -2.02 on trailing EPS of -3.202650165623892 USD.

What do analysts rate AARD?

Analyst consensus is "Buy" across 9 ratings (0 strong buy, 4 buy, 4 hold, 1 sell, 0 strong sell). Average 12-month price target: 3 USD.